Open AccessOrally administered saccharide-sequestering nanocomplex to manage carbohydrate metabolism disorders
Author(s) -
Xin Zhao,
Huijun Zhang,
Jiacheng Li,
Meng Tian,
Juanjuan Yang,
Songxuan Sun,
Qixin Hu,
Lei Yang,
Shiyi Zhang
Publication year - 2021
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.abf7311
Subject(s) - nonalcoholic fatty liver disease , monosaccharide , chemistry , drug , polysaccharide , carbohydrate , lipogenesis , type 2 diabetes , fructose , diabetes mellitus , pharmacology , carbohydrate metabolism , boronic acid , metabolism , biochemistry , medicine , fatty liver , endocrinology , disease , combinatorial chemistry
Excessive carbohydrate intake is linked to the growing prevalence of diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. α-Glucosidases inhibitor, the only Food and Drug Administration-approved drug for limiting the absorption of polysaccharides and disaccharides, is ineffective for monosaccharides. Here, we develop a boronic acid-containing polymer nanocomplex (Nano-Poly-BA), absorbing all saccharides into nanocomplex with the diol/boronic acid molar ratio far above 1, to prevent saccharides' absorption in the gut. The orally administered Nano-Poly-BA is nonabsorbable and nontoxic. When tested against four kinds of carbohydrates and three real-world foods (coke, blueberry jam, and porridge), Nano-Poly-BA shows remarkable after-meal blood glucose reductions in wild-type, type 1, and type 2 diabetic mouse models. In a NAFLD mouse model induced by fructose, Nano-Poly-BA shows substantial reduction of hepatic lipogenesis. In short, the orally administered saccharide-sequestering polymer nanocomplex may help prediabetic, diabetic, overweight, and even healthy people to manage sugar intake.